| 25-Jan-2008 | S | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 25, 2008, inter alia, has taken the following decisions:
1. Sub-division of the Equity Shares Capital of the Company from Rs 10/- per share to Rs 1/- per share.
SUB. :- Sub Division of equity shares of Marksans Pharma Limited (Scrip Code 524404)
Trading members of the Exchange are hereby informed that, Marksans Pharma Limited has fixed the Book Closure for the purpose of sub
division of equity shares of the company.
COMPANY NAME CODE
Marksans Pharma Limited
524404
BOOK CLOSURE
18/03/2008 to 25/03/2008
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into TEN equity shares of Re.1/- each.
SUB-DIVIDED PAID-UP VALUE
Re.1/-
SUB-DIVIDED PAID-UP VALUE W.E.F.
11/03/2008 DR-241/2007- 2008
The auction in the equity shares of Marksans Pharma Limited in Dematerialised Securities - Rolling Settlement Segment on 11/03/2008, 12/03/2008 and 13/03/2008 will be conducted as per face value of Rs.10/- each. Trading members are, therefore, requested to take abundant precautions while mentioning the rates for offering
the equity shares of the said company in auction on the said dates.
The scrip will be No Delivery from 11/03/2008 (DR-241/2007-2008) to 17/03/2008 (DR-245/2007-2008).
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route
Scheme will be for Re.1/- paid up w.e.f. 11/03/2008.
ii. ISIN No. INE750C01018 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 11/03/2008, except for the auction transactions, which will be conducted on 11/03/2008, 12/03/2008 and 13/03/2008 respectively.
iii. The new ISIN Number for Re.1/- paid up will be informed to the market by a separate notice.
(As Per BSE Notice Dated on 04.03.2008) | 18-Mar-2008 | |
| 30-May-2023 | D | Declaration of dividend @ Re. 0.50 (Rupee Zero and Paise Fifty) i.e. 50% per equity
share ofRe. 1/- each face value for the financial year 2022-23 have been approved by the
Board of Directors. The payment of the dividend shall be made on or after 12th June,
2023 to all the members of the Company whose names has been entered on Record Date
i.e 7thJune, 2023. | 07-Jun-2023 | |
| 30-May-2022 | D | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended final dividend @ Re. 0.25 (Rupee Zero and Paise Twenty Five) i.e. 25% per equity share of Re. 1/- each face value for the financial year ended March 31, 2022, subject to approval of the shareholders in the ensuing Annual General Meeting. | 19-Aug-2022 | |
| 31-May-2021 | D | This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Monday, 31st May, 2021 at Mumbai, recommended dividend of Rs. 0.25 (Rupees Zero and Paise Twenty Five) i.e. 25% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2021, subject to approval of the shareholders in the ensuing Annual General Meeting. | 15-Sep-2021 | |
| 02-Jun-2020 | D | This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Tuesday, 2nd June, 2020 at Mumbai, recommended dividend of Rs. 0.10 (Rupees Zero and Paise Ten) i.e. 10% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2020, subject to approval of the shareholders in the ensuing Annual General Meeting.
| 22-Sep-2020 | |
| 29-May-2019 | D | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2019, inter alia, has recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each face value for the financial year ended March 31, 2019, subject to approval of the shareholders in the ensuing Annual General Meeting. | 19-Sep-2019 | |
| 30-May-2018 | D | This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Wednesday, 30th May, 2018 at Mumbai, recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each value for the financial year ended 31st March, 2018, subject to approval of the shareholders in the ensuing Annual General Meeting.
You are requested to note the above in your records. | 19-Sep-2018 | |
| 29-May-2017 | D | the Board of Directors of the Company has, at its meeting held on today i.e. Monday, 29th May, 2017 at Mumbai, recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each value for the financial year ended 31st March, 2017, subject to approval of the shareholders in the ensuing Annual General Meeting. | 19-Sep-2017 | |
| 30-May-2016 | D | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2016, has recommended dividend of Rs. 0.12 (Rupees Zero and Paise Twelve) i.e. 12% per equity share of Re. 1/- each face value for the financial year ended March 31, 2016, subject to approval of the shareholders in the ensuing Annual General Meeting. | 22-Sep-2016 | |
| 30-May-2015 | D | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2015, inter alia, has recommended dividend of Rs. 0.12 (Rupees Zero and Paise Twelve) i.e. 12% per equity share of Re. 1/- each face value for the financial year ended March 31, 2015, subject to approval of the shareholders in the ensuing Annual General Meeting. | 23-Sep-2015 | |
| 29-May-2014 | D | Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2014, inter alia, has recommended dividend of 10% which is Rs. 0.10 per equity share of Rs. 1/- each face value subject to the approval of shareholders in the ensuing Annual General Meeting. | 18-Sep-2014 | |
| 17-Jan-2024 | BC | MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the unaudited financial results (Standalo | 13-Feb-2024 | |
| 27-Oct-2023 | BC | MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve To consider and approve the unaudited fina | 09-Nov-2023 | |
| 02-Aug-2023 | BC | Intimation of Newspaper Publication made pursuant to AGM Notice
31st AGM is scheduled to be held on Monday, 28th August, 2023 through VC/OAVM facility
Annual Report for the Financial Year 2022- | 28-Aug-2023 | |
| 22-Aug-2023 | BC | Arvind Singh
(Acquisition Dated on: 14/08/2023 to 18/08/2023)
| 14-Aug-2023 | |
| 22-Aug-2023 | BC | Arvind Singh
(Sale Dated on: 14/08/2023 to 18/08/2023)
| 14-Aug-2023 | |